Literature DB >> 2117421

Changes in pulmonary circulation in severe bronchopulmonary dysplasia.

A Bush1, C M Busst, W B Knight, A A Hislop, S G Haworth, E A Shinebourne.   

Abstract

Eight patients with severe bronchopulmonary dysplasia underwent cardiac catheterisation. Seven had a pulmonary vascular resistance greater than 3 mm Hg.l-1 min.m2 (mean 8.9, range 2.2-13.8). All had raised intrapulmonary shunts (mean 25.6%, range 5.4-50%, normal less than 5%). Two had a high alveolar dead space, and two had unsuspected congenital heart disease. Epoprostenol (prostacyclin), but not 100% oxygen, caused a significant fall in pulmonary vascular resistance. Death was associated with a high pulmonary vascular resistance and a high shunt. Morphometric studies in three cases showed normal numbers of airways, but increased thickness of bronchial muscle. The numbers of alveoli were reduced and the walls thickened. There was increased medial thickness in small pulmonary arteries with distal extension of muscle. In the oldest child some vessels were obliterated by fibrosis. We speculate that measurements of pulmonary vascular resistance and shunt may have prognostic value; that a trial of pulmonary vasodilators other than oxygen might be worthwhile in patients with poor prognosis; and that abnormalities of the pulmonary circulation contribute to the difficulties of managing patients with bronchopulmonary dysplasia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117421      PMCID: PMC1792458          DOI: 10.1136/adc.65.7.739

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  30 in total

1.  The number of alveoli in the terminal respiratory unit of man during late intrauterine life and childhood.

Authors:  J L EMERY; A MITHAL
Journal:  Arch Dis Child       Date:  1960-12       Impact factor: 3.791

2.  Peripheral pulmonary vascular and airway abnormalities in adolescents with rheumatic mitral stenosis.

Authors:  S G Haworth; S M Hall; M Panja; M Patel
Journal:  Int J Cardiol       Date:  1988-03       Impact factor: 4.164

3.  Pulmonary hypertension in infants with bronchopulmonary dysplasia.

Authors:  G Goodman; R M Perkin; N G Anas; D R Sperling; D A Hicks; M Rowen
Journal:  J Pediatr       Date:  1988-01       Impact factor: 4.406

4.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

5.  Morphologic changes in intrapulmonary veins.

Authors:  C A Wagenvoort
Journal:  Hum Pathol       Date:  1970-06       Impact factor: 3.466

6.  Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?

Authors:  A Bush; C Busst; K Booth; W B Knight; E A Shinebourne
Journal:  Circulation       Date:  1986-07       Impact factor: 29.690

7.  Digital computer subroutine for the conversion of oxygen tension into saturation.

Authors:  G R Kelman
Journal:  J Appl Physiol       Date:  1966-07       Impact factor: 3.531

8.  Pathologic features of long-standing "healed" bronchopulmonary dysplasia: a study of 28 3- to 40-month-old infants.

Authors:  J T Stocker
Journal:  Hum Pathol       Date:  1986-09       Impact factor: 3.466

9.  The effects of preterm delivery and mechanical ventilation on human lung growth.

Authors:  A A Hislop; J S Wigglesworth; R Desai; V Aber
Journal:  Early Hum Dev       Date:  1987-05       Impact factor: 2.079

10.  Long-term follow-up of bronchopulmonary dysplasia.

Authors:  W Berman; R Katz; S M Yabek; T Dillon; R R Fripp; L A Papile
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

View more
  22 in total

1.  Changes in pulmonary arterial pressure in preterm infants with chronic lung disease.

Authors:  N V Subhedar; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  M P White; A B Houston
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

3.  Doppler assessment of pulmonary artery pressure in neonates at risk of chronic lung disease.

Authors:  B H Su; T Watanabe; M Shimizu; M Yanagisawa
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

4.  Mid-childhood outcomes after pre-viable preterm premature rupture of membranes.

Authors:  M H Bentsen; E Satrell; H Reigstad; S L Johnsen; M Vollsæter; O D Røksund; G Greve; A Berg; T Markestad; T Halvorsen
Journal:  J Perinatol       Date:  2017-06-29       Impact factor: 2.521

5.  Pulmonary arteriolar muscle thickening in sudden infant death syndrome.

Authors:  Bradley T Thach; Kathleen A Harris; Henry Krous
Journal:  BMJ Case Rep       Date:  2009-06-01

Review 6.  Progress in understanding the pathogenesis of BPD using the baboon and sheep models.

Authors:  Kurt H Albertine
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

7.  Vasopressin as an adjunct therapy for pulmonary hypertension: a case report.

Authors:  Andra Malikiwi; Arun Sasi; Kenneth Tan; Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2013-12-03       Impact factor: 3.183

8.  Pulmonary artery pressure changes in the very low birthweight infant developing chronic lung disease.

Authors:  A B Gill; A M Weindling
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

9.  Cardiopulmonary function in premature infants with bronchopulmonary dysplasia--a 2-year follow up.

Authors:  T Farstad; F Brockmeier; D Bratlid
Journal:  Eur J Pediatr       Date:  1995-10       Impact factor: 3.183

10.  Assessing pulmonary arterial hypertension in infants with severe chronic lung disease of infancy: a role for a pulmonary artery catheter?

Authors:  Orkun Baloglu; Vincent P R Aluquin; Robert F Tamburro; Neal J Thomas; Steven E Lucking; Gary D Ceneviva; Toah Nkromah; Beth R Schneider; Emily Lewellen; Michael D Dettorre
Journal:  Pediatr Cardiol       Date:  2013-02-14       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.